ONWARD Medical’s ARC Brain-Computer Interface (BCI) System Receives the US FDA’s Breakthrough Device Designation
Shots:
- ONWARD Medical’s ARC-BCI System has received the US FDA’s BDD that utilizes brain-computer interface (BCI) technology + ARC-IM therapy to restore thought-driven lower limb mobility after spinal cord injury (SCI) based on the clinical results from two feasibility studies
- The implanted BCI in the system captures brain activities & signals indicating movement intentions that are decoded into instructions using AI after which the system stimulates the injured spinal cord to restore thought-driven movement after paralysis
- Additionally, in May 2023, the results of feasibility study were published in Nature revealing enhanced control over paralyzed legs on addition of BCI. The company anticipates launch of its first product later in 2024
Ref: ONWARD Medical | Image: ONWARD Medical
Related News:- NurExone Reports Preclinical Results of ExoPTEN for the Treatment of Traumatic Spinal Cord Injuries
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
